Parasutterella excrementihominis Promotes Experimental Colitis and Colitis-Related Colorectal Cancer Through the Induction of Pathogenic NETosis - Takeaways - MDSpire

Parasutterella excrementihominis Promotes Experimental Colitis and Colitis-Related Colorectal Cancer Through the Induction of Pathogenic NETosis

  • By

  • Huishi Tan

  • Linwen Huang

  • Jun Wang

  • Hongli Huang

  • Zelong Lin

  • Siqi Yang

  • Yanqiang Shi

  • Jierui Li

  • Haiyan Zhang

  • Yongjian Zhou

  • Chongyang Huang

  • May 1, 2026

  • 0 min

Share

  • 1

    Parasutterella excrementihominis is enriched in ulcerative colitis patients and linked to increased disease activity.

  • 2

    P. excrementihominis exacerbates experimental colitis and colorectal cancer by inducing pathogenic NETosis through specific metabolites.

  • 3

    The metabolites succinic acid and 6-hydroxyhexanoic acid activate NETosis via succinate receptor 1 and G protein-coupled receptor 84 signaling.

  • 4

    Dysregulated NETosis contributes to mucosal damage and inflammation in ulcerative colitis and colitis-associated colorectal cancer.

  • 5

    Targeting P. excrementihominis or its metabolites may provide new therapeutic strategies for managing ulcerative colitis and colorectal cancer.

Original Source(s)

Parasutterella excrementihominis Promotes Experimental Colitis and Colitis-Related Colorectal Cancer Through the Induction of Pathogenic NETosis

  • by Huishi Tan, Linwen Huang, Jun Wang, Hongli Huang, Zelong Lin, Siqi Yang, Yanqiang Shi, Jierui Li, Haiyan Zhang, Yongjian Zhou, Chongyang Huang

  • May 1, 2026

Related Content

Nitidine chloride suppresses polo-like kinase 1 via MYCN-associated transcriptional regulation in colorectal cancer: a multi-omics and spatial transcriptomics study

The role of NAD+ metabolic reprogramming in colorectal cancer chemoresistance: mechanistic insights, clinical translation challenges and opportunities

Colorectal Cancer Treatment During Pregnancy

Colorectal cancer (CRC) impacts about 1 in 13,000 pregnancies in the United States. This article follows the case of a 36-year-old woman diagnosed with CRC while pregnant and highlights considerations around CRC diagnosis and cancer treatment during pregnancy.